The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Turan T, Say?n MR, Kul S, Akyüz AR

Be aware of misdiagnosis tied to COVID-19 focusing: a case report of abciximab-induced alveolar haemorrhage thought to be SARS-CoV-2 in a patient with ST-segment elevation myocardial infarction.

European heart journal. Case reports 2020 Dec;4;1-6 — 2020 Dec — 1-6

Choi AW, Blair JE, Flaherty JD

Abciximab-induced alveolar hemorrhage treated with rescue extracorporeal membranous oxygenation.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2015 Apr;85;828-31 — 2015 Apr — 828-31

Conrotto F, Scacciatella P, Usmiani T, Grasso C, Ebrille E, D'Amico M, Marra S

Pulmonary hemorrhage and acute pulmonary thromboembolism after abciximab administration.

The American journal of emergency medicine 2013 Feb;31;450.e1-2 — 2013 Feb — 450.e1-2

Mikkilineni H, Bruhl SR, Colyer WR, Pandya U

A retrospective analysis and case series of glycoprotein IIb/IIIa inhibitor associated diffuse alveolar hemorrhage: two case reports.

Cases journal 2009 Jul 30;2;8553 — 2009 Jul 30 — 8553

Vizzardi E, D'Aloia A, Zanini G, Antonioli E, Pedrinazzi C, Raddino R, Dei Cas L

A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome.

Internal and emergency medicine 2008 Dec;3;345-7 — 2008 Dec — 345-7

Conley M, Patino G, Romick B, Almaleh M, Campbell C, Hawkins K, Moore S, Allan P

Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention.

The Canadian journal of cardiology 2008 Feb;24;149-51 — 2008 Feb — 149-51

Usman MH, Shah MA, ul-Islam T, Adenwalla HN, Rahman F, Baqir M, Altaf M, Venkataraman R, Cherayil M, Berger S

Abciximab and fatal pulmonary hemorrhage.

Heart & lung : the journal of critical care 2006 Nov-Dec;35;423-6 — 2006 Nov-Dec — 423-6

Iskandar SB, Kasasbeh ES, Mechleb BK, Garcia I, Jackson A, Fahrig S, Albalbissi K, Henry PD

Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors.

Journal of interventional cardiology 2006 Aug;19;356-63 — 2006 Aug — 356-63

Tan HC, Low A, Ng KS, Budiono B, Sutandar A, Chia BL, Lim YT

Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent.

Singapore medical journal 2002 Nov;43;587-9 — 2002 Nov — 587-9

Choi RK, Lee NH, Lim DS, Hong Sk, Hwang HK

Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy.

Mayo Clinic proceedings 2002 Dec;77;1340-3 — 2002 Dec — 1340-3

Kalra S, Bell MR, Rihal CS

Alveolar hemorrhage as a complication of treatment with abciximab.

Chest 2001 Jul;120;126-31 — 2001 Jul — 126-31

Ali A, Patil S, Grady KJ, Schreiber TL

Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2000 Feb;49;181-4 — 2000 Feb — 181-4

Khanlou H, Tsiodras S, Eiger G, Abousy K, Goldberg S, Nakhjavan F, Yazdanfar S

Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.

Catheterization and cardiovascular diagnosis 1998 Jul;44;313-6 — 1998 Jul — 313-6